UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Journal of clinical oncology, 2023-11, Vol.41 (33), p.5118-5130

2023

Volltextzugriff (PDF)

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of oncology, 2022-12, Vol.33 (12), p.1250-1268

2022

Volltextzugriff (PDF)

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

Annals of oncology, 2020-06, Vol.31 (6), p.674-696

2020

Volltextzugriff (PDF)

Abstract P3-08-13: Exploring the role of ctDNA in triple negative breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-08-13

2019

Volltextzugriff (PDF)

Abstract P4-08-27: The 21-gene Recurrence® (RS) Score assay in estrogen receptor positive node negative breast cancer: Real-world chemotherapy usage and patient characteristics within the intermediate and high-risk RS category

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-08-27

2019

Volltextzugriff (PDF)

Abstract P4-08-03: Looking forward to the TNM 9th edition: Is it time to stage the different breast cancer subtypes as distinct diseases?

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-08-03

2019

Volltextzugriff (PDF)

Abstract P4-08-01: Is the 8th edition of the breast cancer TNM staging system an improvement over the 7th edition?

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-08-01

2019

Volltextzugriff (PDF)

Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD3-10-PD3-10

2019

Volltextzugriff (PDF)

Abstract P1-13-02: Real world outcomes of adjuvant FECD, ddACT and ACT for the treatment of early stage breast cancer - A multicenter retrospective analysis

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-13-02

2019

Volltextzugriff (PDF)

Abstract P5-21-25: Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-25

2018

Volltextzugriff (PDF)

Abstract P5-19-01: Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-19-01

2018

Volltextzugriff (PDF)

Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-03

2018

Volltextzugriff (PDF)

Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-07-06

2017

Volltextzugriff (PDF)

Research needs in breast cancer

Annals of oncology, 2017-02, Vol.28 (2), p.208-217

2017

Volltextzugriff (PDF)

Abstract P5-12-10: Comparison of the efficacy of tamoxifen and aromatase inhibitors on survival in adjuvant menopausal breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-12-10

2016

Volltextzugriff (PDF)

Abstract P3-12-05: The BC provincial experience on FEC-D vs. AC-taxane protocol as adjuvant treatment for breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P3-P3-12-05

2013

Volltextzugriff (PDF)

P1-12-25: Evaluation of PTEN, EGFR and Ki67 Expression as Predictors of Response to a Trastuzumab-Containing Neoadjuvant Chemotherapy Regimen in a HER-2 Over-Expressing Locally Advanced Breast Cancer (LABC) Trial

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P1-P1-12-25

2011

Volltextzugriff (PDF)

P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-14-01

2011

Volltextzugriff (PDF)

P1-06-08: Effect of Treatment Emergent Symptoms on Relapse Free Survival: NCIC CTG MA.12 a Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women in Early Breast Cancer

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P1-P1-06-08

2011

Volltextzugriff (PDF)

P2-14-02: NCIC CTG MA.27: Clinical Tolerability and Overall Survival of Racial and Ethnic Minority Women on Aromatase Inhibitor Therapy

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P2-P2-14-02

2011

Volltextzugriff (PDF)

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen

Annals of oncology, 2007-01, Vol.18 (1), p.45-51

2007

Volltextzugriff (PDF)

Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival

Cancer research (Chicago, Ill.), 2006, Vol.66 (1), p.393-403

2006

Volltextzugriff (PDF)

MDM2 protein expression is a negative prognostic marker in breast carcinoma

Modern pathology, 2006-01, Vol.19 (1), p.69-74

2006

Volltextzugriff (PDF)

A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130

Investigational new drugs, 2005-10, Vol.23 (5), p.445-453

2005

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(57)

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

Abstract P3-08-13: Exploring the role of ctDNA in triple negative breast cancer

Abstract P4-08-27: The 21-gene Recurrence® (RS) Score assay in estrogen receptor positive node negative breast cancer: Real-world chemotherapy usage and patient characteristics within the intermediate and high-risk RS category

Abstract P4-08-03: Looking forward to the TNM 9th edition: Is it time to stage the different breast cancer subtypes as distinct diseases?

Abstract P4-08-01: Is the 8th edition of the breast cancer TNM staging system an improvement over the 7th edition?

Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial

Abstract P1-13-02: Real world outcomes of adjuvant FECD, ddACT and ACT for the treatment of early stage breast cancer - A multicenter retrospective analysis

Abstract P5-21-25: Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2

Abstract P5-19-01: Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer

Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups

Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

Research needs in breast cancer

Abstract P5-12-10: Comparison of the efficacy of tamoxifen and aromatase inhibitors on survival in adjuvant menopausal breast cancer

Abstract P3-12-05: The BC provincial experience on FEC-D vs. AC-taxane protocol as adjuvant treatment for breast cancer

P1-12-25: Evaluation of PTEN, EGFR and Ki67 Expression as Predictors of Response to a Trastuzumab-Containing Neoadjuvant Chemotherapy Regimen in a HER-2 Over-Expressing Locally Advanced Breast Cancer (LABC) Trial

P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis

P1-06-08: Effect of Treatment Emergent Symptoms on Relapse Free Survival: NCIC CTG MA.12 a Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women in Early Breast Cancer

P2-14-02: NCIC CTG MA.27: Clinical Tolerability and Overall Survival of Racial and Ethnic Minority Women on Aromatase Inhibitor Therapy

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen

Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival

MDM2 protein expression is a negative prognostic marker in breast carcinoma

A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130

Suchergebnisse filtern